BJDX - Kewajiban jangka dawa marang modal Bluejay Diagnostics Corp

Logo korporat perusahaan Bluejay Diagnostics Corp (BJDX)

Bluejay Diagnostics (BJDX) develops rapid diagnostic systems, yet a lack of revenue and reliance on new share issuances leave the business extremely vulnerable, as confirmed by the financial price action with the 0.00 indicator. There is a serious threat of failure during product market entry and difficulties with equipment implementation in clinics. The company's strategy relies on independent platform promotion and limited licensing of distribution rights.

Bluejay Diagnostics, Inc. (BJDX): Utang jangka dawa marang modal saka 04.07.2022 nganti 28.10.2026
Barang utama Bluejay Diagnostics

This ratio is calculated by dividing total liabilities with a maturity of over one year by the amount of equity. By analyzing the ratio of long-term loans to equity, an investor determines the degree of financial stability and default risks. A decrease in this metric confirms a reduction in debt, whereas an excess limits business maneuverability. For Bluejay Diagnostics (BJDX), the leverage balance is critical when building a staff of high-caliber researchers. Stable financing allows Bluejay Diagnostics (BJDX) to provide premium working conditions for developers of rapid diagnostic systems.

Karo sapa Bluejay Diagnostics saingan

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc.|Quest - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Illumina Platform (ILMN)|EXAS - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal revvity.com RVTY|Bio-Rad - Utang jangka dawa marang modal|NNNN: Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Sterigenics|QuidelOrtho Inc. (QDEL) - Rasio utang jangka dawa marang modal|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas Fulgent Genetics Inc FLGT|LAB: Rasio utang jangka dawa marang ekuitas|Cytek Corp - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas OSUR (OraSure Technologies)|XGN - Rasio tanggungan utang jangka dawa marang modal|MDxHealth - Utang jangka dawa marang modal|LUCD (Lucid Diagnostics, Inc.) - Rasio tanggungan utang jangka dawa marang modal|PRE: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Insight Molecular|Utang jangka dawa marang modal Trinity Biotech plc (TRIB)|Utang jangka dawa marang ekuitas PRPH (prophaselabs.com)|Utang jangka dawa marang ekuitas Ainos AIMD|CODX - Utang jangka dawa marang ekuitas|Heart Test Laboratories Inc. - Rasio utang jangka dawa marang ekuitas|BMRA - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDIO|VRAX (viraxbiolabs.com) - Kewajiban jangka dawa marang modal|Aspira Women's Health Inc. (AWH) - Utang jangka dawa marang ekuitas|Rasio silihan jangka dawa marang modal Accelerate Diagnostics Inc.|Utang jangka dawa marang modal CNTG|Utang jangka dawa marang modal enzo.com ENZ|FRES: Rasio utang jangka dawa marang ekuitas|GENE - Kewajiban jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas 23andMe (ME)|PMD - Koefisien utang jangka dawa marang modal